entering a new era in the treatment of obesity
Em Nova Orleans, pesquisadores apresentaram resultados que podem redefinir décadas de frustração médica com o tratamento da obesidade. A retatrutida, droga experimental da Eli Lilly, alcançou em ensaio clínico uma perda média de 30% do peso corporal ao longo de dois anos — resultados que, até agora, pertenciam quase exclusivamente ao domínio da cirurgia. O que está em jogo não é apenas a balança, mas o destino cardiovascular de milhões de pessoas que carregam, junto ao peso, o risco silencioso de doenças que se instalam por décadas.
- A retatrutida entregou o que a medicina farmacológica nunca havia conseguido: perda de peso sustentada e comparável à cirurgia bariátrica, sem procedimento cirúrgico.
- Mais de 85% dos participantes perderam ao menos 15% do peso inicial, e um terço chegou ao índice de massa corporal considerado normal — números que reescrevem o que se esperava de um medicamento.
- Os efeitos metabólicos foram tão expressivos quanto a perda de peso: 95% dos pré-diabéticos normalizaram a glicemia, triglicerídeos caíram 41% e a pressão arterial recuou de forma clinicamente significativa.
- Especialistas presentes à conferência da Associação Americana de Diabetes usaram a palavra 'histórico' com cautela, mas a usaram — reconhecendo que a ciência cruzou um limiar que não existia antes.
- A droga ainda é experimental, a aprovação regulatória não chegou e o acesso real permanece incerto, deixando a promessa suspensa entre o laboratório e a vida cotidiana dos pacientes.
Em Nova Orleans, no congresso anual da Associação Americana de Diabetes, pesquisadores apresentaram os resultados do estudo TRIUMPH-1, o maior ensaio clínico já realizado com a retatrutida, droga experimental desenvolvida pela Eli Lilly. O que os dados mostraram surpreendeu até quem acompanhava os estudos preliminares: ao longo de 104 semanas, pacientes que usaram a injeção semanal perderam, em média, 30% do peso corporal.
O estudo reuniu mais de 2.300 pessoas com sobrepeso e comorbidades associadas — apneia do sono, osteoartrite, distúrbios metabólicos. Após 80 semanas, a perda média já havia chegado a 28,3%. Mais de um quarto dos participantes eliminou 35% ou mais do peso inicial. Dois terços reduziram o IMC abaixo de 30, saindo da faixa de obesidade. Um terço chegou ao intervalo considerado normal.
Mas foram os marcadores metabólicos que chamaram mais atenção. Entre os participantes com pré-diabetes, mais de 95% normalizaram a glicemia. Os triglicerídeos caíram 41%. O LDL recuou quase 20%. A pressão sistólica diminuiu 12,3 mmHg. Clayton Macedo, endocrinologista e diretor da Sociedade Brasileira de Endocrinologia e Metabologia, que assistiu à apresentação presencialmente, afirmou que as melhorias metabólicas são 'capazes de alterar profundamente o risco cardiovascular a longo prazo'.
Macedo escolheu as palavras com cuidado, mas não evitou o peso delas: 'É difícil não reconhecer este como um momento histórico diante da obesidade.' Para ele, os resultados confirmam que a medicina está entrando em uma nova era no tratamento de uma doença crônica, complexa e multifatorial. Os efeitos colaterais relatados foram predominantemente gastrointestinais, mais intensos em doses maiores, mas manejáveis.
A retatrutida ainda aguarda aprovação regulatória. O acesso real ao medicamento permanece uma incógnita. Mas a ciência, ao menos, avançou para um território que antes pertencia apenas à cirurgia.
In New Orleans last week, at the annual conference of the American Diabetes Association, researchers presented results from what may be the most consequential obesity study in years. The drug at the center of it—retatrutida, made by Eli Lilly—achieved something that has long eluded pharmaceutical treatment: sustained weight loss comparable to surgery, without the knife.
Over 104 weeks, patients using the weekly injection lost an average of 30 percent of their body weight. The main trial, called TRIUMPH-1, enrolled more than 2,300 people who were overweight and carried the usual companions of excess weight: osteoarthritis, sleep apnea, metabolic disorder. After 80 weeks of treatment, the average loss had reached 28.3 percent. More than 85 percent of participants shed at least 15 percent of their starting weight. More than a quarter dropped 35 percent or more. Two-thirds brought their BMI below 30—the threshold for obesity itself. One-third fell below 25, into the normal range.
But the numbers that struck observers most were not about weight alone. Among participants who entered the trial with prediabetes, more than 95 percent normalized their blood sugar. Triglycerides fell by 41 percent. LDL cholesterol—the kind that builds in arteries—dropped nearly 20 percent. Systolic blood pressure fell by 12.3 millimeters of mercury. These are not cosmetic changes. They are the markers that determine whether someone will have a heart attack or stroke in twenty years. Clayton Macedo, an endocrinologist and director of Brazil's Society of Endocrinology and Metabolism, who watched the presentation in person, called the metabolic improvements "capable of profoundly altering long-term cardiovascular risk."
Macedo, who also teaches at Unifesp, used careful language when describing what he had seen. "It is difficult not to recognize this as a historic moment in the face of obesity," he said. The preliminary studies had suggested retatrutida might work. But this trial confirmed it: the drug had reached "an unprecedented level of efficacy among pharmaceutical therapies for obesity." The results, he noted, approached what bariatric surgery achieves—the gold standard against which all weight-loss treatments are measured.
Patients also reported improvements in the conditions that obesity had created. Sleep apnea improved. Knee osteoarthritis eased. The side effects were those expected from this class of drug: mostly gastrointestinal complaints, worse at higher doses, manageable.
Macedo framed the moment in the language of medicine's long arc. "As a clinical endocrinologist, professor, and researcher, I consider that the data presented today reinforce that we are entering a new era in the treatment of obesity—a chronic, complex, and multifactorial disease." The drug is still experimental. Regulatory approval has not yet come. Real-world access remains uncertain. But the science, at least, has moved. The question now is what comes next.
Citas Notables
Difficult not to recognize this as a historic moment in the face of obesity— Clayton Macedo, endocrinologist and director of Brazil's Society of Endocrinology and Metabolism
The drug has reached an unprecedented level of efficacy among pharmaceutical therapies for obesity— Clayton Macedo
La Conversación del Hearth Otra perspectiva de la historia
Why does a 30 percent weight loss matter so much? People lose weight all the time.
Because this is sustained, and because it comes with metabolic healing. You're not just smaller—your blood sugar normalizes, your cholesterol improves, your blood pressure drops. The cardiovascular risk profile changes fundamentally.
But it's still a drug. Doesn't the weight come back when you stop taking it?
That's the honest question. The trial ran 104 weeks. What happens after is unknown. That's why they call it experimental.
The bariatric surgery comparison—is that fair? Surgery is permanent.
In some ways, yes. But surgery also carries real risk, requires hospitalization, changes anatomy. A weekly injection is not nothing, but it's different. And for people who can't or won't have surgery, this opens a door that was closed.
What about cost? Who gets this?
That's the question no one answered at the conference. Eli Lilly makes expensive drugs. Access will depend on insurance, on country, on wealth. The science works. The equity question is separate and unsolved.
So this is a beginning, not an ending.
Exactly. The drug works. Now comes everything else—approval, manufacturing, pricing, real-world use, long-term safety. The hard part.